In the phase III trial, postmenopausal women with ER-positive, HER2-nonamplified advanced breast cancer who had progressed on prior aromatase inhibitors were randomized in a 2:1 ratio to receive oral everolimus (10 mg daily) or placebo, in combination with exemestane (25 mg daily). The gene discussed is CYP19A1; the disease is breast carcinoma.